| Product Code: ETC11704773 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Daratumumab Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Daratumumab Market Revenues & Volume, 2021 & 2031F |
3.3 China Daratumumab Market - Industry Life Cycle |
3.4 China Daratumumab Market - Porter's Five Forces |
3.5 China Daratumumab Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 China Daratumumab Market Revenues & Volume Share, By Technology Type, 2021 & 2031F |
3.7 China Daratumumab Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.8 China Daratumumab Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 China Daratumumab Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of multiple myeloma in China |
4.2.2 Growing adoption of targeted therapies for cancer treatment |
4.2.3 Favorable government policies supporting the healthcare sector in China |
4.3 Market Restraints |
4.3.1 High cost associated with daratumumab treatment |
4.3.2 Limited awareness about daratumumab among healthcare professionals and patients in China |
4.3.3 Stringent regulatory requirements for drug approval in China |
5 China Daratumumab Market Trends |
6 China Daratumumab Market, By Types |
6.1 China Daratumumab Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 China Daratumumab Market Revenues & Volume, By Product Type, 2021 - 2031F |
6.1.3 China Daratumumab Market Revenues & Volume, By Injectable Daratumumab, 2021 - 2031F |
6.1.4 China Daratumumab Market Revenues & Volume, By Daratumumab Biosimilar, 2021 - 2031F |
6.1.5 China Daratumumab Market Revenues & Volume, By Combination Therapy, 2021 - 2031F |
6.1.6 China Daratumumab Market Revenues & Volume, By Oral Daratumumab, 2021 - 2031F |
6.2 China Daratumumab Market, By Technology Type |
6.2.1 Overview and Analysis |
6.2.2 China Daratumumab Market Revenues & Volume, By Monoclonal Antibody, 2021 - 2031F |
6.2.3 China Daratumumab Market Revenues & Volume, By Biosimilar Technology, 2021 - 2031F |
6.2.4 China Daratumumab Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.2.5 China Daratumumab Market Revenues & Volume, By Oral Drug Delivery, 2021 - 2031F |
6.3 China Daratumumab Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 China Daratumumab Market Revenues & Volume, By Oncologists, 2021 - 2031F |
6.3.3 China Daratumumab Market Revenues & Volume, By Healthcare Providers, 2021 - 2031F |
6.3.4 China Daratumumab Market Revenues & Volume, By Cancer Patients, 2021 - 2031F |
6.3.5 China Daratumumab Market Revenues & Volume, By Cancer Treatment Centers, 2021 - 2031F |
6.4 China Daratumumab Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 China Daratumumab Market Revenues & Volume, By Multiple Myeloma Treatment, 2021 - 2031F |
6.4.3 China Daratumumab Market Revenues & Volume, By Cancer Therapy, 2021 - 2031F |
6.4.4 China Daratumumab Market Revenues & Volume, By Co-Therapy with Chemotherapy, 2021 - 2031F |
6.4.5 China Daratumumab Market Revenues & Volume, By Advanced Myeloma Care, 2021 - 2031F |
7 China Daratumumab Market Import-Export Trade Statistics |
7.1 China Daratumumab Market Export to Major Countries |
7.2 China Daratumumab Market Imports from Major Countries |
8 China Daratumumab Market Key Performance Indicators |
8.1 Patient enrollment in clinical trials for daratumumab |
8.2 Number of healthcare facilities offering daratumumab treatment |
8.3 Rate of reimbursement approval for daratumumab therapy by insurance providers |
9 China Daratumumab Market - Opportunity Assessment |
9.1 China Daratumumab Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 China Daratumumab Market Opportunity Assessment, By Technology Type, 2021 & 2031F |
9.3 China Daratumumab Market Opportunity Assessment, By End User, 2021 & 2031F |
9.4 China Daratumumab Market Opportunity Assessment, By Application, 2021 & 2031F |
10 China Daratumumab Market - Competitive Landscape |
10.1 China Daratumumab Market Revenue Share, By Companies, 2024 |
10.2 China Daratumumab Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here